GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Profitability Rank

Artgen Biotech PJSC (MIC:ABIO) Profitability Rank : 6 (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Profitability Rank?

Artgen Biotech PJSC has the Profitability Rank of 6.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Artgen Biotech PJSC's Operating Margin % for the quarter that ended in Jun. 2023 was 12.65%. As of today, Artgen Biotech PJSC's Piotroski F-Score is 5.


Competitive Comparison of Artgen Biotech PJSC's Profitability Rank

For the Biotechnology subindustry, Artgen Biotech PJSC's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's Profitability Rank falls into.



Artgen Biotech PJSC Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Artgen Biotech PJSC has the Profitability Rank of 6.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Artgen Biotech PJSC's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=78.596 / 621.115
=12.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Artgen Biotech PJSC has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Artgen Biotech PJSC Profitability Rank Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC (MIC:ABIO) Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.